Riskpilot← Back to searchSign inGet full accessOptimum Pharma Solutions Nordic AB
ABBankruptOrg 5569040701Business and other management consultancy activities · NACE 7022Est. 20121 employees
Revenue 2021
SEK 82K
-83% vs 2020
EBITDA margin
28.9%
+101% vs 2020
Equity ratio
16.8%
Financial strength
Net profit 2021
SEK 2K
+100% vs 2020
| Revenue | SEK 82K | -83% |
| EBITDA | SEK 24K | +101% |
| Net profit | SEK 2K | +100% |
| Total assets | SEK 1,3M | -25% |
| Equity | SEK 212K | +1% |
| Employees | 1 | — |
Legal name
Optimum Pharma Solutions Nordic AB
Org number
5569040701
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
18 september 2012
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Styrelsen ska bestå av 1 styrelseledamot och 1 styrelsesuppleant.
Company purpose
Bolaget skall bedriva konsulttjänster inom företagsorganisation, strategi och ledarskapsutveckling, bedriva verksamhet inom casemetodik samt samt kvalitetsprojekt gentemot läkare och läkemedelsbolag, reklambyråverksamhet, PR och marknadsföring samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 2 232 | 1 363 | 475 | 82 |
| Staff expenses | — | — | — | — | −0 |
| EBITDA | −5 | 734 | −471 | −2 410 | 24 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −5 | 734 | −471 | −2 410 | 24 |
| Net financials | — | −1 | — | −2 | −21 |
| Profit before tax | −5 | 734 | −471 | −2 412 | 2 |
| Tax | −0 | −161 | −0 | −0 | — |
| Net profit | −5 | 573 | −471 | −2 412 | 2 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 37 | 1 223 | 1 025 | 1 689 | 1 262 |
| Equity | 37 | 610 | 122 | 209 | 212 |
| Long-term debt | 0 | 0 | 505 | 5 | 0 |
| Short-term debt | 0 | 613 | 399 | 1 475 | 1 050 |
| Total debt | — | 613 | 904 | 1 480 | 1 050 |
EBITDA margin
28.9%
This company
15.8%
Market median
+83% vs market
20172021
Equity ratio
16.8%
This company
38.2%
Market median
-56% vs market
20172021
Return on equity
1.1%
This company
18.4%
Market median
-94% vs market
20172021
Net profit margin
2.9%
This company
8.1%
Market median
-64% vs market
20172021
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20172021
Debt / equity
4.96×
This company
0.62×
Market median
-700% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
| Former (3) | ||
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Optimum Pharma Solutions Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Agneta Lisbeth Monica Gustafsson | Deputy Board Member | 0 companies |
| Tommy Arne Berglind | Board of Directors | 0 companies |
| Kim Archara Berglind | Deputy Board Member | 0 companies |
| Hans Ingvar Fritiof Gustafsson | Board of Directors | 0 companies |